原发性胆汁性胆管炎:个体化二线治疗
本文综述原发性胆汁性胆管炎(PBC)二线治疗的个体化选择。PBC 为靶向小叶内小胆管的自身免疫病,主要累及中年女性,诊断依据胆汁淤积性肝功能指标与高度特异的抗线粒体抗体。熊去氧胆酸为基础治疗,可延缓多数患者疾病进展,但对 PBC 症状无影响。大型队列研究证实,最大化降低血清碱性磷酸酶水平有获益,应答不充分者需加用二线药物。
要点
- PBC 主要累及中年女性,诊断依据胆汁淤积性肝功能指标与高度特异的抗线粒体抗体。
- 熊去氧胆酸可延缓多数患者疾病进展,但对 PBC 症状无影响。
- 大型队列研究证实最大化降低血清碱性磷酸酶水平有益,应答不充分者需加用二线药物。
核心结论
- 熊去氧胆酸为 PBC 基础治疗,可延缓多数患者疾病进展但对症状无影响;应答不充分者需加用二线药物,选择时需考虑患者特征以实现个体化。
研究设计与样本
- 本文为综述,围绕 PBC 二线治疗的个体化选择,汇总胆汁酸生理学进展及新型药物的相关证据。
主要发现
- 奥贝胆酸是首个获批用于 PBC 的二线治疗,可显著改善肝脏生化指标并与长期临床结局改善相关,但因其易诱发瘙痒而受限。
- Elafibranor 与 seladelpar 为过氧化物酶体增殖物激活受体激动剂,近期获批用于 PBC 患者。
- 贝扎贝特与非诺贝特为超说明书用药,在熊去氧胆酸应答不充分的患者中亦显示生化指标改善,并可能改善瘙痒症状。
关键数值与推荐
- 熊去氧胆酸应答不充分者需加用二线药物;大型队列研究证实最大化降低血清碱性磷酸酶水平有获益。
- 奥贝胆酸为已获批的二线治疗,可显著改善肝脏生化指标,但易诱发瘙痒。
- Elafibranor 与 seladelpar 为近期获批用于 PBC 的过氧化物酶体增殖物激活受体激动剂。
- 贝扎贝特与非诺贝特为超说明书用药,亦显示生化指标改善,并可能改善瘙痒。
临床怎么用
- 原文建议在决定是否启用二线药物及选择何种药物时,应考虑患者特征,以实现真正个体化的 PBC 患者管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis. Primarily affecting middle-aged women, the diagnosis of PBC is typically straightforward, with most patients presenting with cholestatic liver tests and the highly specific antimitochondrial antibody. For decades, the foundational treatment of PBC has been ursodeoxycholic acid, which delays disease progression in most patients but has no impact on PBC symptoms. Large cohort studies of patients with PBC have established the benefit of maximizing the reduction in serum alkaline phosphatase levels with ursodeoxycholic acid and the need to add second-line agents in patients who do not achieve an adequate response. Advances in the understanding of bile acid physiology have led to the development of new agents that improve cholestasis in patients with PBC and are predicted to reduce the risk of disease progression. Obeticholic acid, the first second-line therapy to be approved for PBC, significantly improves liver biochemistries and has been associated with improved long-term clinical outcomes but is limited by its propensity to induce pruritus. Elafibranor and seladelpar are peroxisome proliferator-activated receptor agonists recently approved for use in patients with PBC, whereas bezafibrate and fenofibrate are available as off-label therapies. They also have shown biochemical improvements among patients with an inadequate response to ursodeoxycholic acid but may improve symptoms of pruritus. Herein, we review the patient features to consider when deciding whether a second-line agent is indicated and which agent to consider for a truly personalized approach to PBC patient care.
引用
- Levy C, Bowlus CL. Primary biliary cholangitis: Personalizing second-line therapies. Hepatology. 2024. PMID: 39707635. doi:10.1097/HEP.0000000000001166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。